Ebola Kills Treated Liberia Doctor

ebolaALiberian doctor has died despite taking an experimental anti-Ebola drug, Liberia’s information minister says.

Abraham Borbor was one of three doctors in Liberia who had been given ZMapp and were showing signs of recovery.

ZMapp has been credited with helping several patients recover, including two US doctors.

More than 1,400 people have died from Ebola this year in four West African countries – Guinea, Liberia, Nigeria and Sierra Leone.

Dr Borbor “was showing signs of improvement but yesterday (Sunday) he took a turn for the worse,” Liberian Information Minister Lewis Brown told the BBC.

“What this means for the drugs, I don’t know,” the minister added, without giving further details.

It is believed Dr Borbor died in the capital Monrovia. He was the deputy chief medical doctor at the country’s largest hospital.

Liberia has recently imposed a quarantine in parts of Monrovia to try to stop the spread of the virus.

Last Thursday, police fired live rounds and tear gas during protests among residents of the city’s West Point slum. Liberia has seen the most deaths — more than 570 – in what is now the worst Ebola outbreak in history.

In a separate development yesterday, a UK volunteer nurse is being treated at a London hospital after contracting Ebola in Sierra Leone – the first confirmed case of a Briton contracting the virus in the current outbreak.

William Pooley, 29, returned to the UK on Sunday and is being kept in a special isolation unit.

Supplies of Zmapp are thought to have been used up and he is not currently being treated with the drug. However, officials have not ruled the use of Zmapp or similar treatments. His family said he was receiving “excellent care”.

Meanwhile, Japan said it was ready to allow shipments of an experimental anti-viral drug to help combat the Ebola outbreak.

It is not clear whether T-705 (or Avigan) will actually work against Ebola, and no monkey or human trials of the drug have been done, the BBC’s Rupert Wingfield-Hayes in Tokyo reports.

T-705 was developed by Japan’s Toyama Chemicals company for use against new strains of influenza. It was approved by the Japanese government earlier this year.

BBC

 

 

email
Print Friendly

Leave a Comment